TY - JOUR
T1 - High-dose-rate brachytherapy using molds for lip and oral cavity tumors
AU - Unetsubo, Teruhisa
AU - Matsuzaki, Hidenobu
AU - Takemoto, Mitsuhiro
AU - Katsui, Kuniaki
AU - Hara, Marina
AU - Katayama, Norihisa
AU - Waki, Takahiro
AU - Kanazawa, Susumu
AU - Asaumi, Jun ichi
N1 - Publisher Copyright:
© 2015 Unetsubo et al.; licensee BioMed Central.
PY - 2015/4/8
Y1 - 2015/4/8
N2 - Background: High-dose-rate (HDR) brachytherapy using the mold technique is a less invasive treatment for early lip and oral cavity cancer. However, limited reports exist regarding the feasibility of this method. In this retrospective study, we evaluated the outcome of this therapy and investigated its feasibility for lip and oral cavity tumors. Methods: Between May 2002 and December 2010, 17 patients (median age, 80.0years) with histologically confirmed squamous cell carcinoma of the lip or oral cavity were treated by means of HDR brachytherapy using the mold technique after external beam radiotherapy (EBRT). Tumor sites included the buccal mucosa in eight cases, the gingiva in three cases, the lips in two cases, the floor of the mouth in two cases, and the hard palate in two cases. For all patients, EBRT (30Gy/15 fractions), was performed before HDR brachytherapy. Two 6-Gy fractions were delivered twice daily for 2days a week with an interval of 6hours between the fractions. The total HDR brachytherapy dose was 24Gy. Prior to EBRT, two patients with neck metastasis underwent neck dissection, and one patient with an exophytic tumor underwent tumor resection. Results: The median follow-up period was 53.4 (range, 4.8-83.4) months. Of the 17 patients, 14 (82.4%) achieved a complete response, and three (17.6%) displayed a partial response. Conclusions: Although there is a need to improve the technical aspects of the treatment protocol, HDR brachytherapy using the mold technique might be a therapeutic option for superficial lip or oral cavity tumors, especially in older patients who have a poor performance status or are in poor physical condition.
AB - Background: High-dose-rate (HDR) brachytherapy using the mold technique is a less invasive treatment for early lip and oral cavity cancer. However, limited reports exist regarding the feasibility of this method. In this retrospective study, we evaluated the outcome of this therapy and investigated its feasibility for lip and oral cavity tumors. Methods: Between May 2002 and December 2010, 17 patients (median age, 80.0years) with histologically confirmed squamous cell carcinoma of the lip or oral cavity were treated by means of HDR brachytherapy using the mold technique after external beam radiotherapy (EBRT). Tumor sites included the buccal mucosa in eight cases, the gingiva in three cases, the lips in two cases, the floor of the mouth in two cases, and the hard palate in two cases. For all patients, EBRT (30Gy/15 fractions), was performed before HDR brachytherapy. Two 6-Gy fractions were delivered twice daily for 2days a week with an interval of 6hours between the fractions. The total HDR brachytherapy dose was 24Gy. Prior to EBRT, two patients with neck metastasis underwent neck dissection, and one patient with an exophytic tumor underwent tumor resection. Results: The median follow-up period was 53.4 (range, 4.8-83.4) months. Of the 17 patients, 14 (82.4%) achieved a complete response, and three (17.6%) displayed a partial response. Conclusions: Although there is a need to improve the technical aspects of the treatment protocol, HDR brachytherapy using the mold technique might be a therapeutic option for superficial lip or oral cavity tumors, especially in older patients who have a poor performance status or are in poor physical condition.
KW - Brachytherapy
KW - High-dose-rate
KW - Lip cancer
KW - Mold
KW - Oral cavity cancer
UR - http://www.scopus.com/inward/record.url?scp=84931274639&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931274639&partnerID=8YFLogxK
U2 - 10.1186/s13014-015-0390-z
DO - 10.1186/s13014-015-0390-z
M3 - Article
C2 - 25888772
AN - SCOPUS:84931274639
VL - 10
JO - Radiation Oncology
JF - Radiation Oncology
SN - 1748-717X
IS - 1
M1 - 81
ER -